Bio-Techne (NSDQ:TECH) and Kantaro Biosciences announced a partnership to manufacture and distribute COVID-19 serology tests.
Kantaro, a commercial affiliate of the Mount Sinai Health System in New York, will collaborate with Bio-Techne to develop a test kit based on the Mount Sinai-developed coronavirus test and scale the manufacturing and distribution of those kits. The companies formed a joint commercialization and distribution team to support the rapid distribution of the assay.
Initial kit production capacity is expected to allow laboratories to conduct more than 10 million tests monthly, starting in July and scaling to higher capacity in the following months.
Mount Sinai’s test kit, which received FDA emergency use authorization (EUA) in April, is an enzyme-linked immunosorbent assay (ELISA) for measuring the presence or absence of anti-COVID-19 antibodies and the level of antibodies a person has produced. It uses a blood-draw designed for ea…